CA Patent

CA2606719A1 — Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same

Assigned to Eisai R&D Management Co Ltd · Expires 2006-12-28 · 19y expired

What this patent protects

An amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)~aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

USPTO Abstract

An amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)~aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CA2606719A1
Jurisdiction: CA
Classification: —
Expires: 2006-12-28
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.